Abstract
A reduction of neurosteroids in the brain may initiate sporadic Alzheimers disease (AD) which comprises > 99% of all AD cases. AD research is currently focused on aberrant amyloid precursor protein (APP) processing and the hyper-phosphorylation of tau protein. This is based on early-onset genetic and pathological observations clearly showing that these markers are involved in the progression of the disease. However, there is still ongoing debate as to the key pathological events in the sporadic form of AD where the Aβ and tau genes are not usually mutated. The vulnerability of the transentorhinal cortex, which displays the first architectural signs of AD, may be related to its role as the entry point for an enormous amount of excitatory information, the majority from the neocortex, which passes through the hippocampal formation. Neurosteroids provide a layer of protection from excessive excitation, and their age-related decrease may expose the vulnerability required to allow neuronal death by excitotoxicity and thereby initiate the disease.
Keywords: Sporadic (AD), Neurosteroids, hyper-phosphorylation, tau protein, transentorhinal cortex, neocortex, excitotoxicity
Current Alzheimer Research
Title: Neurosteroids and Sporadic Alzheimers Disease
Volume: 5 Issue: 4
Author(s): Guy Barry and Ian L. Ross
Affiliation:
Keywords: Sporadic (AD), Neurosteroids, hyper-phosphorylation, tau protein, transentorhinal cortex, neocortex, excitotoxicity
Abstract: A reduction of neurosteroids in the brain may initiate sporadic Alzheimers disease (AD) which comprises > 99% of all AD cases. AD research is currently focused on aberrant amyloid precursor protein (APP) processing and the hyper-phosphorylation of tau protein. This is based on early-onset genetic and pathological observations clearly showing that these markers are involved in the progression of the disease. However, there is still ongoing debate as to the key pathological events in the sporadic form of AD where the Aβ and tau genes are not usually mutated. The vulnerability of the transentorhinal cortex, which displays the first architectural signs of AD, may be related to its role as the entry point for an enormous amount of excitatory information, the majority from the neocortex, which passes through the hippocampal formation. Neurosteroids provide a layer of protection from excessive excitation, and their age-related decrease may expose the vulnerability required to allow neuronal death by excitotoxicity and thereby initiate the disease.
Export Options
About this article
Cite this article as:
Barry Guy and Ross L. Ian, Neurosteroids and Sporadic Alzheimers Disease, Current Alzheimer Research 2008; 5 (4) . https://dx.doi.org/10.2174/156720508785132325
DOI https://dx.doi.org/10.2174/156720508785132325 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Improvement of a Novel Proposal for Antioxidant Treatment Against Brain Damage Occurring in Ischemic Stroke Patients
CNS & Neurological Disorders - Drug Targets Gene-modified Mesenchymal Stem Cell–based Therapy in Renal Ischemia- Reperfusion Injury
Current Gene Therapy Gene Therapy with Transcription Factor Decoy Oligonucleotides as a Potential Treatment for Cardiovascular Diseases
Current Drug Targets Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Cardioprotective Effects of Indian Gooseberry (Emblica officinalis Gaertn) and its Phytochemicals: A Review
Current Nutrition & Food Science Ipsilateral Hippocampal Proteomics Reveals Mitochondrial Antioxidative Stress Impairment in Cortical-Lesioned Chronic Mild Stressed Rats
Current Molecular Medicine Host Stress and Virulence Expression in Intestinal Pathogens: Development of Therapeutic Strategies Using Mice and C. elegans
Current Pharmaceutical Design TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma
Current Neuropharmacology Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Caspase-1 as Molecular Key in Cardiac Remodeling during Cardiorenal Syndrome Type 3 in the Murine Model
Current Molecular Medicine Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design Sirolimus Early Graft Nephrotoxicity: Clinical and Experimental Data
Current Drug Safety Cardiac Adrenomedullin: Its Role in Cardiac Hypertrophy and Heart Failure
Current Medicinal Chemistry - Cardiovascular & Hematological Agents